BioRestorative Therapies, Inc. (NASDAQ:BRTX) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET
Company Participants
Stephen Kilmer – Investor Relations
Lance Alstodt – Chairman and Chief Executive Officer
Francisco Silva – Vice President-Research and Development
Conference Call Participants
Jonathan Aschoff – ROTH Capital
Michael Okunewitch – Maxim Group
Elemer Piros – Rodman
Operator
Greetings. Welcome to the BioRestorative Third Quarter 2024 Results and New Additional Preliminary BRTX-100 Phase 2 Study Data Review Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] Please note, this conference is being recorded.
I will now turn the conference over to your host, Stephen Kilmer, Investor Relations. You may begin.
Stephen Kilmer
Thank you. Good afternoon, everyone. Let me start by pointing out that this conference call will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are based on BioRestorative Therapies’ current beliefs, assumptions and expectations. And such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. No forward-looking statement can be guaranteed.
For details on factors among others, that could affect expectations, see Part 1, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2023, as amended, and Part 2, Item 1A of our Quarterly Report on Form 10-Q for the period ended September 30, 2024, filed with the Securities and Exchange Commission. Listeners are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date of this conference call.
BioRestorative undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise other than as required by law on the call.
On the call, representing the company are Lance Alstodt, BioRestorative’s Chairman and Chief Executive Officer; Francisco Silva, its Vice President of Research and Development, and Robert Kristal, the company’s Chief Financial Officer.
With that said, I’ll now turn the call over to Lance.
Lance Alstodt
Thanks, Steve and good afternoon, everyone. Welcome to the call. On behalf of the management team and everyone here at BioRestorative, I’d like to thank you for your interest in our company and for those of you who are shareholders, we obviously appreciate your support.